Scri Development Innovations, Llc

This study tests two drugs, tucatinib and Doxil, together in people with HER2+ breast cancer that has spread. The goal is to see how well the combination shrinks tumors and to track any side effects. About 36 adults with advanced disease will take part.

This study tests a combination of two treatments (fruquintinib plus FOLFIRI) in people with metastatic colorectal cancer whose disease has worsened after first-line therapy. About 60 participants will receive the drug combo to see if it can stop or slow cancer growth. The goal is…

This study tests whether a combination of two drugs (elranatamab and daratumumab) can work as well as or better than a stem cell transplant followed by maintenance therapy for people newly diagnosed with multiple myeloma. About 100 participants will be randomly assigned to one of…

This study tests whether a new drug combination (BMS-986489) works better than the current standard drug (durvalumab) as follow-up treatment after chemoradiation for limited-stage small cell lung cancer. About 250 adults will take part. The goal is to see if the new combo helps p…

This study tests whether two multiple myeloma drugs, teclistamab and talquetamab, can be given safely in an outpatient clinic instead of requiring a hospital stay. About 100 adults with multiple myeloma who have tried at least one prior treatment will receive preventive medicine …